Anti-Human CD20 (Ofatumumab) (C3170-1.0mg)

CD20 is a transmembrane protein that is prominently present on the surface of B-cells from the early to mature stages, but notably absent on hematopoietic stem cells, pro-B cells, or plasma cells. Its significance lies in its role in B-cell functions such as activation and differentiation. It is a key target for monoclonal antibodies used in the treatment of B-cell- related diseases and autoimmune conditions. Monoclonal antibodies targeting CD20 have been widely used to treat B-cell lymphomas, leukemias, and autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. These antibodies work by selectively targeting and depleting B-cells that express CD20, thereby modulating the immune response and reducing inflammation. This targeted approach has shown promising results in managing various B-cell disorders and has significantly improved the prognosis for patients with these conditions1,2. Ofatumumab, also known as OMB 157, is an anti-CD20 monoclonal antibody specifically developed to treat relapsing multiple sclerosis (RMS). Administered through subcutaneous injection, this medication functions by selectively binding to the CD20 molecule on B cells, inducing their destruction and subsequent reduction in number. Clinical studies have demonstrated the potential of ofatumumab in reducing disease activity in individuals with relapsing multiple sclerosis, highlighting its promise as a therapeutic option in the management of this condition3,4.